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Analysis of mutations in pncA 
reveals non-overlapping patterns 
among various lineages of 
Mycobacterium tuberculosis
Ramani Baddam1,6, Narender Kumar2, Lothar H. Wieler1, Aditya Kumar Lankapalli3,7,  
Niyaz Ahmed3,4, Sharon J. Peacock  2,5 & Torsten Semmler  1
Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug, resistance to which occurs 
primarily due to mutations in pncA (Rv2043c) that encodes the pyrazinamidase enzyme responsible for 
conversion of pro-drug PZA into its active form. Previous studies have reported numerous resistance-
conferring mutations distributed across the entire length of pncA without any hotspot regions. As 
different lineages of Mycobacterium tuberculosis display a strong geographic association, we sought 
to understand whether the genetic background influenced the distribution of mutations in pncA. 
We analyzed the whole genome sequence data of 1,480 clinical isolates representing four major M. 
tuberculosis lineages to identify the distribution of mutations in the complete operon (Rv2044c-pncA-
Rv2042c) and its upstream promoter region. We observed a non-overlapping pattern of mutations 
among various lineages and identified a lineage 3-specific frame-shift deletion in gene Rv2044c 
upstream of pncA that disrupted the stop codon and led to its fusion with pncA. This resulted in the 
addition of a novel domain of unknown function (DUF2784) to the pyrazinamidase enzyme. The variant 
molecule was computationally modelled and physico-chemical parameters determined to ascertain 
stability. Although the functional impact of this mutation remains unknown, its lineage specific nature 
highlights the importance of genetic background and warrants further study.
Mycobacterium tuberculosis poses a huge burden on global health, the effective treatment of which is becoming 
increasingly complex as drug resistance spreads worldwide1. According to a WHO report published in 2015 only 
one in four multidrug resistant-TB cases are diagnosed2, highlighting the need for rapid and accurate diagnostic 
tools. To this end, whole genome sequencing (WGS) offers a better alternative than current methods3. In the 
last few years, many WGS projects have been undertaken around the world to catalogue genetic determinants 
associated with phenotypic resistance4–6. These have largely focused on two key areas. The first is to improve the 
accuracy in predicting phenotypic resistance based on genetic information, which could then be implemented 
as an alternative to conventional drug susceptibility testing (DST) and other diagnostic tests. The second is to 
detect novel mutations associated with drug resistance that are not captured in the current catalogue. Studies have 
shown the diagnostic potential of WGS to achieve higher diagnostic sensitivity and specificity for some drugs6–8, 
but further work is required to improve the accuracy of prediction for several first and second line drugs that 
form the core of anti-TB treatment. This includes pyrazinamide (PZA), resistance to which is mainly due to the 
acquisition of mutations in pncA (Rv2043c) that impairs the conversion of the pro-drug PZA into its active form 
pyrazinoic acid9. This first-line drug is likely to remain indispensable owing to its bactericidal activity against the 
persister bacterial sub-population10.
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Low sensitivity in predicting PZA resistance is largely due to the large number of pncA gene mutations 
observed in phenotypically resistant isolates without clear hotspots for mutations, which poses significant hurdles 
for the development of genotypic assays9,11. Alternative assays such as high-resolution melt analysis (real-time 
PCR based) that detect variations in the entire pncA sequence and upstream promoter region are also limited by 
the inability to detect genetic events such as transversions or small deletions12. Furthermore, phenotypic screen-
ing of PZA resistance is challenging since its optimal bactericidal effect requires a low pH, which can lead to 
inconsistent results13.
Previous studies have reported that the propensity to acquire drug resistance varies among different lineages 
of M. tuberculosis14. For example, strains belonging to the East Asian lineage (lineage 2) were observed to acquire 
drug resistance more rapidly than other lineages15. Furthermore, strains of different lineages carrying the same 
resistance mutations have been observed to have different MIC levels for the corresponding drug. These observa-
tions clearly highlight the importance of bacterial genetic background16. The mechanisms for this lineage specific 
behavior is surmised to be multifactorial17,18, but is poorly understood and requires investigation. It also indicates 
a need to explore hitherto unknown associations between lineage specific variations and their impact on drug 
resistance.
Given the above and taking into account the multiplicity of mutations observed in pncA gene, we first deter-
mined the lineage-wise distribution of resistance conferring mutations identified in a phenotypically PZA resist-
ant strain collection. As pncA is part of a larger operon comprising of two additional genes, we also identified the 
distribution of all mutations in the complete operon and its upstream promoter region using a collection of nearly 
one and a half thousand M. tuberculosis isolates chosen irrespective of their phenotype6, mainly to analyze if there 
exists any lineage specific differences that could impact on PZA susceptibility. This led to the identification of a 
lineage 3 specific frame-shift deletion in Rv2044c gene upstream of pncA which resulted in the fusion of these two 
genes. This added an additional domain of unknown function to the pyrazinamidase enzyme. The variant pncA 
molecule in lineage 3 was computationally modeled and physico-chemical parameters determined and compared 
to the native molecule. This study emphasizes the importance of analyzing lineage-specific mutations and their 
potential impact on drug resistance mechanisms in M. tuberculosis.
Results
Lineage-wise distribution of resistance determining mutations in pncA. The genome sequence 
data of 254 phenotypically PZA resistant isolates representing four major lineages - 18 isolates of lineage 1 (7.1%), 
149 isolates of lineage 2 (58.7%), 32 isolates of lineage 3 (12.6%) and 55 isolates of lineage 4 (21.7%) - were ana-
lyzed to identify the resistance determining mutations in gene pncA (including 40 bp upstream region). Out of 254 
strains investigated, resistance determining mutations were observed in 181 isolates (71.2%) comprising 8 isolates 
of lineage 1, 118 isolates of lineage 2, 24 isolates of lineage 3 and 31 isolates of lineage 4. Complete information for 
these mutations is provided in Supplementary Table S1. The lineage-wise distribution of resistance determining 
mutations and their frequency at each distinct position along the gene are shown in Fig. 1. This clearly showed an 
absence of overlap among lineages at 85% of the positions where mutations were identified, for example as shown 
at positions 202 and 385. Mutations that confer resistance in M. tuberculosis are generally acquired via convergent 
evolution in different lineages, an example being mutations in rpoB that confers resistance to rifampicin and are 
Figure. 1. Lineage-wise distribution of resistance determining mutations. The frequency of resistance 
determining mutations at each distinct position along the gene pncA (including upstream promoter region) 
were analyzed and their lineage information is represented as distinct colored bars. The mutations were 
spread all across the gene pncA and minimal overlap is observed among the strains of different lineages at any 
particular positon.
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concentrated in the rifampicin resistance determining region19 as shown in Supplementary Figure S1 (complete 
details available in Supplementary Information). By contrast, here we observed that resistance determining muta-
tions were distributed across pncA with minimal overlap observed between strains of different lineages at any 
particular position.
Lineage-wise distribution of mutations in the complete operon (Rv2044c-pncA-Rv2042c). 
Genome sequence data for 1480 M. tuberculosis isolates belonging to the major lineages were selected irrespec-
tive of phenotype from publically accessible genomes that were generated by a previous study6. The process for 
selecting isolates is described in the methodology. Our collection represented all four major lineages - 141 isolates 
of lineage 1 (9.5%), 91 isolates of lineage 2 (6.1%), 315 isolates of lineage 3 (21. 3%) and 933 isolates of lineage 
4 (63%). It was previously reported that pncA (Rv2043c) is co-transcribed as a polycistron along with Rv2044c 
located 40 base pairs (bp) upstream to pncA, and Rv2042c is located immediately downstream with a 1 bp overlap 
with pncA20. To capture this entire region, 1801bp sequence of H37Rv reference strain (NC_000962.3) corre-
sponding to the complete operon (Rv2044c-pncA-Rv2042c) together with 85 bp upstream (to include the pro-
moter region for the operon) was used for variant calling with GATK HaplotypeCaller. After filtering for variants 
using metrics described in the methodology, mutations were detected at 68 distinct positions in the operon. The 
lineage-wise distribution of all the single nucleotide polymorphisms (SNP) and insertion/deletion (indels) sites 
is shown in Table 1. Complete details of genetic variants at each position and their frequency are provided in 
Supplementary Table S2.
Figure 2 illustrates the position and frequency of the genetic variant alleles at each of these 68 distinct posi-
tions along the operon. Variant positions rarely overlapped in different lineages, with two exceptions. The first 
was present in pncA where a single nucleotide deletion (GT/773/G) was identified in lineage 1 strains and a 
SNP (G/773/C) at the same locus in lineage 3 strains. The other variant position was present in Rv2042c where 
No. of indel sites No. of SNP sites
Lineage 1 2 9
Lineage 2 0 11
Lineage 3 5 10
Lineage 4 4 29
Table 1. Comparative statistics of single nucleotide polymorphism (SNP) and insertion/deletion (indels) sites 
observed among different lineages.
Figure 2. Lineage-wise distribution of mutations in the complete operon (Rv2044c-pncA-Rv2042c). The 
frequency of mutations at each distinct position along the operon (-85bp -Rv2044c-Rv2043c(pncA)-Rv2042c) 
were determined and their lineage information represented above. The position of mutation corresponds to 
location in the operon and different colors represent genes in which they are identified – Rv2044c (brown), 
intergenic region (black), Rv2043c (green), Rv2042c (blue). The two genetic variants showed lineage specific 
behavior being present in 97% of isolates belonging to that lineage and completely absent in others, as follows - 
single nucleotide deletion (GCCG/232/GCG) in Rv2044c observed in isolates of lineage 3 and SNP (C1515G) in 
Rv2042c observed in isolates of lineage 2.
www.nature.com/scientificreports/
4Scientific RepoRTs | (2018) 8:4628 | DOI:10.1038/s41598-018-22883-9
lineage 1 strains carried a SNP (G/1305/A) whereas lineage 4 strains harbored SNP (G/1305/C) at the same locus 
(Supplementary Table S2).
Our analysis also identified variants at two positions that were highly specific to strains of a particular line-
age (present in 97% of isolates belonging to that lineage and absent in the remaining isolates/lineages) as shown 
in Fig. 2. The first was a SNP (C1515G) in Rv2042c in lineage 2 isolates, and the second was a single nucleo-
tide deletion (GCCG/232/GCG) in Rv2044c in lineage 3 isolates. Apart from the above mentioned two variants, 
SNP (C553T) in pncA was observed in 81% of lineage 3 isolates. This has been reported previously as a lineage 
3-associated silent mutation (Ser65Ser)19, which was absent in a small number of basal isolates of this lineage.
Effect of lineage-specific variations. The lineage 2 specific SNP (C/1515/G) in Rv2042c was a synon-
ymous substitution with no change in amino acid sequence. By contrast, the deletion of a single nucleotide 
(GCCG/GCG) at position 232 in Rv2044c caused a frameshift that disrupted the stop codon and resulted in fusion 
of Rv2044c with the downstream pncA to create a hybrid molecule consisting of 305 amino acids only in lineage 3 
of M. tuberculosis as shown in Fig. 3. In silico analysis of this hybrid molecule using NCBI CD-search21 indicated 
the addition of a new domain of unknown function (DUF2784) previously encoded by Rv2044c to the variant 
pncA of lineage 3. The DUF2784 domain is reported to be a conserved domain in bacteria, but has not been 
functionally characterized. This observation led us to analyze the status of these genes (Rv2044c-pncA-Rv2042c) 
in other lineages of MTBC, non-tuberculous mycobacteria (NTM) and M. canettii to evaluate its evolutionary 
significance.
Comparison of (Rv2044c-pncA-Rv2042c) in MTBC and M. canettii. M. tuberculosis belongs to the 
Mycobacterium tuberculosis complex (MTBC), which contains other human and animal adapted lineages includ-
ing M. africanum and M. bovis, respectively22. Different MTBC lineages have evolved clonally over time after their 
divergence from the common ancestor with smooth tubercle bacilli, M. canettii23. A NCBI BLASTn24 comparison 
was carried out to determine the orthologs of genes Rv2044c-pncA-Rv2042c as well as to identify whether the 
deletion in Rv2044c was present in other members of the MTBC and M. canettii. As shown in Fig. 3 (a compar-
ison made using EasyFig25), these genes are highly conserved among various lineages of MTBC and M. canettii, 
but the lineage 3 specific frameshift deletion in Rv2044c was not identified in representative isolates of all other 
lineages considered, hinting that the deletion may have occurred post lineage diversification in M. tuberculosis. 
The status of these genes in the majority of NTM isolates has been already reported in a previous study26.
Modeling of variant pyrazinamidase enzyme of M. tuberculosis lineage 3. Physicochemical prop-
erties of the variant PncA molecule were compared to the native PncA protein using ProtParam, a summary from 
which is shown in Table 2. The isoelectric point of the variant PncA protein indicates that the variant protein is 
more basic compared to the native protein. An increase in the number of positively charged residues was also 
observed. An instability index of less than 40 for both proteins along with similar aliphatic indices indicates that 
both proteins are stable. An increase in GRAVY score indicates that the variant PncA protein is more hydropho-
bic compared with the native protein.
Figure 3. Comparison of (Rv2044c-pncA-Rv2042c) in MTBC and M. canettii. Comparison of genes Rv2044c 
(pink), pncA (brown) and Rv2042c (blue) among different lineages of Mycobacterium tuberculosis complex and 
Mycobacterium canettii reveal a high degree of conservation. A frameshift deletion (arrow in black) in Rv2044c 
resulted in its fusion with pncA gene which was restricted to isolates of Lineage 3 (variant in orange). Conserved 
regions are represented using the gradient scale in grey.
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The crystal structure of native pyrazinamidase has been determined by Petrella et al.27, and was available in 
the RSCB Protein Databank (PDB). An in silico evaluation was performed to determine a representative confor-
mation of the variant pyrazinamidase enzyme in equilibrium. 3D modelling was performed using I-TASSER soft-
ware, and refinement of the protein 3D model was performed in multiple steps to address the lack of homology to 
the extended region in the variant enzyme (see methodology). The final model with the highest confidence score 
contained 31.4% Alpha helix, 9.5% Strand, 2.9% 3–10 helix, and the remainder included mainly Coil, as shown in 
Fig. 4. The Ramachandran plot assessment of residues of the 3D model using RAMPAGE revealed 87.8% residues 
in favorable region, 7.3% in allowed region, and 5% comprised outliers. This final model was further subjected 
to MD simulations for 35 ns using Gromacs and the stability and conformational changes were analyzed. The 
flattening of the RMSD plot of the protein backbone around 35 ns in Fig. 5A indicated that the molecule achieved 
a stationary phase during the later stages of simulation and showed fluctuations around 5.4 A° at the end of sim-
ulations. The plot of gyration radius was also stable around 2.4 A° with no major modifications in the secondary 
structure of the protein, representing the compactness of the protein during the simulation as shown in Fig. 5B. 
The total energy trajectory remained stable over the entire simulation period at around −1.018e + 3 KJ/mol, as 
shown in Fig. 5C. Ramachandran plot analysis of the model obtained after MD simulation depicted 86.8% resi-
dues in favorable region, 10.3% in allowed region and 3.0% in disallowed regions.
Discussion
M. tuberculosis has co-evolved with humans over time, which has led to the emergence of different geograph-
ically compartmentalized bacterial lineages28. Genetic diversity of these lineages may influence both virulence 
and transmission potential29. In addition, strains from specific lineages have been shown to have an increased 
capacity to acquire resistance or mitigate the associated fitness cost30. This supports the importance of a detailed 
understanding of the effect of genetic background on biological traits, including drug resistance. The genetic 
Protein pncA (native) pncA (L3 lineage)
No. of amino acids 186 305
Molecular weight 19604.64 32931.31
Theoretical pI 4.43 6.25
No. of negatively charged residues (Asp + Glu) 27 30
No. of positively charged residues (Arg + Lys) 10 26
Instability index 10.35 29.97
Aliphatic index 83.92 83.51
Grand average of hydropathicity (GRAVY) 0.002 0.055
Table 2. In silico comparison of physico-chemical properties of original PncA molecule with that of variant one 
observed only in lineage 3.
Figure 4. 3D structure of the variant pyrazinamidase molecule. The 3D structure was visualised using Pymol - 
Helix (cyan), sheets (magenta) and coil(brown).
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variation among lineages is also pertinent in relation to pyrazinamide where resistance conferring mutations are 
diverse and distributed across pncA. Hence, we analyzed the lineage wise distribution of mutations in the operon 
comprised of Rv2044c, pncA and Rv2042c.
We identified an important frameshift deletion in Rv2044c affecting pncA that was restricted to M. tuberculosis 
lineage 3. This frameshift deletion disrupted the stop codon of Rv2044c, and the hybrid molecule composed of the 
two genes effectively increased length of PncA by 119 amino acids. As pncA is reported to be expressed as part of 
a polycistronic mRNA product of the operon20, any effect on expression due to this deletion would be minimal. 
This observation is supported by the evidence of enzymatic activity in lineage 3 isolates harboring this deletion, 
as reported recently by Miotto et al.31. In their study on pyrazinamide resistance, sequencing of pncA was carried 
out for 1950 clinical isolates and upstream promoter region (>100 bp) was also included for a small number of 
isolates.
This strongly suggests that the lineage-specific variation identified in this study does not disrupt pyrazinam-
idase enzyme activity and that a variant enzyme with an additional domain DUF2784 of unknown function is 
transcribed in isolates of lineage 3. Furthermore, structural refinement of the 3D model obtained from I-TASSER 
using MD simulations showed that the variant molecule is stable as displayed by the trajectories of RMSD, total 
energy and radius of gyration for 35 ns, which validates the conformation of the predicted structure. Minor fluc-
tuations observed in the trajectories could be attributed to the presence of coil regions in the protein model, 
which are difficult to stabilize during the simulations. However, functional studies comparing the native and 
variant PncA are necessary to elucidate the role of the additional domain and its full impact on enzyme function.
To evolve from an environmental bacterium into a human restricted professional pathogen, M. tuberculosis 
could have selected many of the attributes that are found commonly in non-tuberculous mycobacteria (NTM) 
and smooth tubercle bacilli (M. canettii). A previous study that compared genomes of MTBC with 11 other 
related NTM species comprising both free living environmental bacteria and opportunistic pathogens26 revealed 
that orthologs of Rv2042c and pncA were conserved in the majority of NTM except for M. leprae, which has 
undergone extensive genome reduction32. The third member of the operon (Rv2044c ortholog) was absent in the 
majority of NTMs including slow growing species such as M. marinum, M. leprae and M. avium, the exception 
being M. smegmatis. The evolution of different slow growing mycobacterial species from their common ances-
tor involved the acquisition or deletion of various important genes that are species-specific or shared by small 
Figure 5. Model refinement analysis using gromacs - (A) RMSD, (B) Radius of gyration, (C) Total Energy. The 
flattening of the RMSD plot of the protein backbone was observed around 35 ns as shown in (A). The plot of 
gyration radius was also stable around 2.4 A° representing the compactness of the protein during the simulation 
as shown in (B). The total energy trajectory remained stable over the entire simulation period at around 
−1.018e + 3 KJ/mol, as shown in (C).
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number of slow growing mycobacteria33,34. The presence of orthologs of Rv20444c in a limited number of slow 
growing mycobacterial species and all MTBC members indicates its importance in the latter. Although all mem-
bers of the MTBC harbor an ortholog of Rv2044c, the evolutionary fixation of the frameshift deletion in lineage 
3 isolates identified here strongly suggests that the variant pncA represents a beneficial adaptive change in the 
associated geographical setting.
A recent multi-country surveillance report which assessed levels of pyrazinamide and rifampicin resistance in 
five different high burden countries observed that levels of pyrazinamide resistance were significantly lower com-
pared to the levels of rifampicin resistance only in Pakistan35. Although this study did not report lineage infor-
mation, other reports have shown the predominance of lineage 3 in Pakistan and Northern India (Delhi)36–38. 
This raises the possibility of alternative mechanisms of pyrazinamidase enzyme action in these strains. Therefore, 
mechanisms by which M. tuberculosis lineage 3 strains acquire PZA resistance need careful investigation.
The genetic background constituted by lineage specific non-resistance conferring mutations might influence 
drug resistance and amelioration of their impact through epistatic interactions17. To our knowledge, our study is 
the first to report the effect of a lineage-specific non-resistance mutation on the drug resistance associated gene, 
pncA. Moreover, this study highlights the need for examination of lineage-specific variations, mainly indels whose 
downstream effect is commonly not estimated compared to SNPs. Minimal overlap in the position of variants 
between lineages could be affected by the limited number of isolates tested for some lineages. Future studies 
of large bacterial collections containing under-sampled lineages promise to yield better resolution and provide 
deeper insights into the dynamics of resistance acquisition.
Methods
Screening for mutations. Intitially, the read data of 254 strains reported as phenotypically resistant to PZA 
were considered from two previous studies6,37 in order to identify the resistance determining mutations along the 
gene pncA. The sequence reads were aligned to the region of H37Rv corresponding to pncA gene including 40 bp 
upstream region. Further, to identify all the genetic variants along the operon, out of 3651 genome sequences 
made available by a previous study from Walker et al.6, the read data that fulfilled the following criteria were 
chosen randomly irrespective of phenotype - read length of 75 bp,100 bp and 101 bp with coverage greater than or 
equal to 100× (complete accession details are provided in Supplementary Table S3). These were downloaded from 
the NCBI sequence read archive using the SRA tool kit39. The sequence reads belonging to different lineages of 
M. tuberculosis were aligned to the region of H37Rv corresponding to (Rv2044c-pncA-Rv2042c) genes and 85 bp 
upstream to identify variants.
Variant calling and annotation. This variant calling step involved generation of an alignment file using 
bwa-mem40 and further processed using Picard tools41 to mark duplicate reads before applying the GATK 
HaplotypeCaller42. All variations called in the VCF (variant call format) file were filtered for metrics – QUAL 
(>50), DP (>10), MQ (>40), QD (>20). Further, filtering based on AD values was performed to include only 
those sites where reads supporting alternate allele were greater than or equal to 75 percent of total reads aligned 
at that position. The annotation of variants and identification of resistance determining ones was done using 
in-house written python scripts. The effect of lineage specific mutations were visualized using Expasy translate 
tool43 and confirmed with gene prediction software GeneMarkS44.
Domain identification and structure analysis of variant protein. The prediction of domains was 
done using NCBI CD-search21. Physico-chemical properties (molecular weight, theoretical PI, instability index45, 
aliphatic index46, GRAVY score47) were determined for the native and variant proteins using Prot-Param server48. 
The three-dimensional (3D) model of the variant protein comprising 305 amino acids (aa) was initially predicted 
by ab-inito modeling in I-TASSER online server49. The top 10 threading templates detected by the I-TASSER 
included a template file corresponding to the original pyrazinamidase crystal structure (3PL1-186 aa) PDB as 
the top most alignment, but also none of the other templates had any alignment to the newly added region of the 
protein. In order to overcome this effect, the first 119 aa sequence which did not have any reported alignment was 
modeled ab-initio separately again using I-TASSER server. In the last step, the model obtained in previous run 
for first part of the protein was provided as a user template while submitting complete sequence to I-TASSER for 
final 3D modeling.
The best model obtained in final run was chosen based on C-score and visualized in PyMOL50 before subject-
ing to structure refinement and validation analysis. Molecular Dynamics (MD) simulations were performed using 
GROMACS version 5.1.451. This mainly included topology generation with GROMOS96 54a7 force field in an 
aqueous environment, solvation of defined cubic box, neutralization of charge using 4 sodium ions and geometry 
optimization. Initial unconstrained global dynamics was carried out in two steps - temperature (300 K) for 100 
picoseconds followed by Pressure (1 bar) for 100 picoseconds. The final step of MD simulations for 35 nanosec-
onds was performed at pressure (1 bar) and temperature (300 K).The Ramachandran plots of variant pyrazinam-
idase before MD simulation and final one obtained after MD simulation were compared using RAMPAGE tool52.
Data Availbility Statement. All the read data analysed is availble on NCBI and accession details are 
provided.
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